{
    "clinical_study": {
        "@rank": "67036", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: Dose Escalation (Lirilumab 0.1mg/kg+Nivolumab 3mg/kg)", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab 0.1 mg/kg solution intravenously every 4 weeks for 8-96 weeks depending on response\nNivolumab 3 mg/kg solution intravenously every 2 weeks for 8-96 weeks depending on response"
            }, 
            {
                "arm_group_label": "Arm 2: Dose Escalation (Lirilumab 0.3mg/kg+Nivolumab 3mg/kg)", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab 0.3 mg/kg solution intravenously every 4 weeks for 8-96 weeks depending on response\nNivolumab 3 mg/kg solution intravenously every 2 weeks for 8-96 weeks depending on response"
            }, 
            {
                "arm_group_label": "Arm 3: Dose Escalation (Lirilumab 1mg/kg+Nivolumab 3mg/kg)", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab 1 mg/kg solution intravenously every 4 weeks for 8-96 weeks depending on response\nNivolumab 3 mg/kg solution intravenously every 2 weeks for 8-96 weeks depending on response"
            }, 
            {
                "arm_group_label": "Arm 4: Dose Escalation (Lirilumab 3mg/kg+Nivolumab 3mg/kg)", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab 3 mg/kg solution intravenously every 4 weeks for 8-96 weeks depending on response\nNivolumab 3 mg/kg solution intravenously every 2 weeks for 8-96 weeks depending on response"
            }, 
            {
                "arm_group_label": "Arm 5: Various Solid Tumors", 
                "arm_group_type": "Experimental", 
                "description": "Lirilumab 3 mg/kg solution intravenously every 4 weeks for 8-96 weeks depending on response\nNivolumab 3 mg/kg solution intravenously every 2 weeks for 8-96 weeks depending on response"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of BMS-986015 given in\n      combination with BMS-936558 and to identify dose limiting toxicities (DLTs) and the\n      maximally tolerated dose (MTD) of the combination, in subjects with advanced (metastatic\n      and/or unresectable) solid tumors."
        }, 
        "brief_title": "A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "CANCER,NOS", 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  During dose escalation, subjects with advanced solid tumors (except for primary CNS\n             metastases) that have progressed following at least one standard regimen\n\n          -  During cohort expansion, subjects with various solid tumors that have received at\n             least one and no more than 5 prior treatment regimens\n\n          -  Subjects must have measurable disease\n\n          -  Subject must consent to provide previously collected tumor tissue. Mandatory\n             on-treatment biopsies for selected tumor types in cohort expansion phase\n\n          -  Women and men \u226518 years of age with performance status of 0 or 1\n\n          -  At least 4 weeks since any previous treatment for cancer\n\n        Exclusion Criteria:\n\n          -  Prior therapy with an immune cell modulating antibody except for anti-Cytotoxic T\n             Lymphocyte Antigen 4 (CTLA4)\n\n          -  Active or chronic autoimmune diseases\n\n          -  Uncontrolled or significant cardiovascular disease\n\n          -  Chronic hepatitis (except for subjects with hepatocellular carcinoma)\n\n          -  Active infection\n\n          -  Active Central nervous system (CNS) metastases\n\n          -  Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome((HIV/AIDS)\n\n          -  Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except\n             for subjects with hepatocellular carcinoma)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714739", 
            "org_study_id": "CA223-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1: Dose Escalation (Lirilumab 0.1mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 2: Dose Escalation (Lirilumab 0.3mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 3: Dose Escalation (Lirilumab 1mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 4: Dose Escalation (Lirilumab 3mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 5: Various Solid Tumors"
                ], 
                "description": "KIR = Killer-cell Immunoglobulin-like Receptors", 
                "intervention_name": "Lirilumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BMS-986015", 
                    "IPH-2102", 
                    "ANTI-KIR"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm 1: Dose Escalation (Lirilumab 0.1mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 2: Dose Escalation (Lirilumab 0.3mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 3: Dose Escalation (Lirilumab 1mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 4: Dose Escalation (Lirilumab 3mg/kg+Nivolumab 3mg/kg)", 
                    "Arm 5: Various Solid Tumors"
                ], 
                "intervention_name": "Nivolumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BMS-936558", 
                    "ANTI-PD1"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Thomas F Gajewski, Site 0005", 
                    "phone": "773-834-1942"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University Of Chicago Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Sharfman, Site 0002", 
                    "phone": "410-502-5352"
                }, 
                "facility": {
                    "address": {
                        "city": "Lutherville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21093"
                    }, 
                    "name": "Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Faber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0001", 
                    "phone": "617-582-7545"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Neil Segal, Site 0003", 
                    "phone": "646-888-3359"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Ctr"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rachel Sanborn, Site 0004", 
                    "phone": "503-215-2604"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97213"
                    }, 
                    "name": "Providence Portland Med Ctr"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 27 months"
            }, 
            {
                "measure": "Safety and tolerability of BMS-986015 given in combination with BMS-936558 as measured by incidence of clinical laboratory test abnormalities including hematology and serum chemistry, and thyroid panel abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 27 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714739"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Every 8 weeks during the Treatment Period (Cycle 1 Day 1 through Cycle 12 Day 56), and once during clinical follow-up\nRECIST = Response Evaluation Criteria In Solid Tumors", 
                "measure": "Anti-tumor activity will be based on Best overall response (BOR), Objective response rate (ORR), Duration of Response (DOR) and Progression-Free Survival Rate (PFSR) using Immune-related RECIST (irRECIST) and RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately up to 27 months"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax) of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Time of maximum observed serum concentration (Tmax) of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Trough observed serum concentration (Ctrough) of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Clearance (CL) of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Volume of distribution at steady state (Vss) of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "Half-life (t1/2) of BMS-986015 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "13 time points up to 27 months"
            }, 
            {
                "measure": "End of infusion of BMS-936558 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "9 time points up to 27 months"
            }, 
            {
                "measure": "Trough observed concentration (Cmin) of BMS-936558 derived from serum concentration versus time", 
                "safety_issue": "Yes", 
                "time_frame": "9 time points up to 27 months"
            }, 
            {
                "measure": "Immunogenicity of BMS-986015 and BMS-936558 measured by occurrence of specific anti-drug antibodies to BMS-986015 and BMS-936558", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 27 months"
            }, 
            {
                "measure": "Measures of Tumor infiltrating lymphocyte(s) (TILs), Programmed Death Ligand-1 (PD-L1) and Human Leukocyte Antigen (HLA) Class I expression using immunohistochemistry", 
                "safety_issue": "No", 
                "time_frame": "Screening (Day -28 to -1) and Day 112"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}